Popularized in films like Limitless, legal smart drugs called Nootropics are becoming more and more prevalent in board rooms and on Wall Street.Keep reading »
Eliot Spitzer is back doing one of the things he is good at doing: Wall-Street sheriffing. (He may or may not be back to doing some of the other things he is good at doing, but neither we nor, to the best of our knowledge, the U.S. Attorney’s Office, is aware of it.)
In any event, to announce his backing of an Israeli start-up that takes aim at some of Spitz’s old nemeses, stock analysts, Eliot was back doing one of the things he proved less good at, television, albeit not on CNN.
“This is more important for investors,” he said. “This isn’t whether they are doing it intentionally. This is simply, are they good or bad?”
Mr. Spitzer has been involved with TipRanks, which recently closed a $3 million funding round, since it was founded in June 2012. The company uses algorithms and other technology to scan articles for financial recommendations and measure the performance of anyone giving investment advice on financial blogs and websites.